



OPEN ACCESS

EDITED BY

Roshan Kumar,
Medical College of Wisconsin, United States

REVIEWED BY

Lei Zhao,
First Affiliated Hospital of Harbin Medical
University, China
Shafiq Shaikh,
Medical College of Wisconsin, United States

*CORRESPONDENCE

Huai-Wu Jiang
✉ jhuaiwu@163.com

†These authors have contributed equally to
this work

RECEIVED 10 September 2024

ACCEPTED 24 December 2024

PUBLISHED 24 January 2025

CITATION

Yang Y, Zhou H-Y, Zhou G-M, Chen J,
Ming R, Zhang D and Jiang H-W (2025) The
impact of different gastrointestinal
reconstruction techniques on gut
microbiota after gastric cancer surgery.
Front. Microbiol. 15:1494049.
doi: 10.3389/fmicb.2024.1494049

COPYRIGHT

© 2025 Yang, Zhou, Zhou, Chen, Ming,
Zhang and Jiang. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

The impact of different gastrointestinal reconstruction techniques on gut microbiota after gastric cancer surgery

Yu Yang^{1,2†}, Hang-Yu Zhou^{2†}, Guo-Min Zhou^{1,2}, Jin Chen²,
Rui Ming², Dong Zhang² and Huai-Wu Jiang^{1,2*}

¹Department of Gastrointestinal Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, ²Department of Gastrointestinal Surgery, Mianyang 404 Hospital, Mianyang, Sichuan, China

Introduction: Gastric cancer is one of the common malignant tumors in the digestive tract, characterized by high incidence and mortality rates. This is particularly significant in China, where a large proportion of global new cases of gastric cancer and related deaths occur. In recent years, with the continuous development of molecular biology technology, people have gained a deeper understanding of the gastrointestinal microbiome, and studies have shown that it is closely related to the occurrence, development, and therapeutic response of gastric cancer. Although surgical intervention is crucial in significantly extending the survival of gastric cancer patients, the disruption of the balance of the intestinal microbiota caused by surgery itself should not be overlooked, as it may affect postoperative recovery.

Methods: This study was approved by the Biomedical Ethics Committee of Sichuan Mianyang 404 Hospital. A random sampling method was used to select patients who underwent gastric cancer surgery at the hospital from January 2023 to December 2023. All patients signed written informed consent forms. Standardized perioperative management was conducted for the patients in the study, including preoperative preparation, intraoperative handling, and postoperative treatment. Fecal samples were collected from patients before surgery (before bowel preparation) and around one week after surgery for 16S rRNA sequencing analysis, through which differential biomarkers and related functional genes were sought.

Results: The study results indicated that there was no significant difference in the diversity of the gut microbiota between the two groups. Compared with the R-Y group, the DTR surgical method significantly altered the structure of the gut microbiota, affecting the types, quantities, and proportions of intestinal bacteria. Furthermore, the DTR group exhibited poorer postoperative nutritional absorption capacity compared to the R-Y group, as indicated by a lower F/B ratio. The R-Y group showed a richer abundance of Bacteroidetes and a lower abundance of Proteobacteria, as well as a higher F/B ratio after surgery. These findings provide new insights into the changes in the gut microbiota following gastric cancer surgery, which may be of significant importance for postoperative recovery and long-term health management.

Discussion: This study reveals the impact of different gastrointestinal reconstruction techniques on the postoperative gut microbiota of gastric cancer patients, providing new insights into the physiological changes during the postoperative recovery period. Although there was no significant difference in microbial diversity between the DTR group and the R-Y group, the DTR group showed more pronounced changes in microbial structure postoperatively, which may be associated with an increased risk of postoperative infection. These findings emphasize the importance of considering the impact on the gut microbiota when selecting gastric cancer surgery methods. However, the study had a limited sample size and did not delve into changes in metabolites. Future studies should expand the sample size and conduct metabolomic analyses to further validate these preliminary findings.

KEYWORDS

gastric cancer, gut microbiota, 16S rRNA sequencing, double tract reconstruction, Roux-en-Y gastrointestinal reconstruction

1 Introduction

Gastric cancer, a common malignant tumor in the digestive tract, is marked by high incidence and mortality rates. According to statistical data from the International Agency for Research on Cancer (IARC) (Pizzato et al., 2022), there are as many as 1.089 million new cases of gastric cancer globally each year, with 769,000 deaths, ranking it fifth among all malignant tumors in terms of incidence and fourth in mortality. It is noteworthy that the incidence and mortality of gastric cancer are particularly prominent in China. Approximately 42.6% of global gastric cancer incidence and 45% of gastric cancer-related deaths occur in China (GBD 2017 Stomach Cancer Collaborators, 2020), closely linked to the low rates of early gastric cancer screening and diagnosis in the country. Early detection of precancerous lesions of gastric cancer (PLGC) and prevention of their progression are crucial for reducing the incidence of gastric cancer.

In recent years, the gastrointestinal microbiome has become a hot topic of research. With the continuous development of molecular biology techniques, 16S rRNA technology, metagenomic research, and high-throughput sequencing technology, we have gained a deeper understanding of the gastric microbiota. These technologies provide strong support for the study of gastric microecology. Research indicates that the gastrointestinal microbiota accounts for about 76% of the human microbiota (Moossavi and Azad, 2019), including a variety of microorganisms such as bacteria, viruses, and fungi, among which bacteria play a dominant role, together forming a complex microbial ecosystem (Laukens et al., 2016). It is worth mentioning that recent breakthroughs have been made in the study of the pathogenesis of gastric cancer, with a growing body of evidence pointing to a close relationship between gastric cancer and the dysregulation of bacteria in the stomach, especially the infection of *Helicobacter pylori* (*H. pylori*). This bacterium can cause chronic gastritis and gastric ulcers, and may also induce malignant transformation of gastric mucosal cells under

long-term chronic stimulation (GBD 2017 Stomach Cancer Collaborators, 2020). At the same time, the gut microbiota also has an important impact on the occurrence, development, and therapeutic response of gastric cancer (Kubota et al., 2014; Kanda et al., 2019).

Although surgical intervention is pivotal in significantly prolonging the survival of gastric cancer patients, the iatrogenic trauma inherent in the procedure exerts a non-negligible effect on the equilibrium of the gut microbiota. Empirical evidence suggests that the stress induced by surgical trauma can modulate the permeability of the intestinal mucosa postoperatively, precipitating dysbiosis, which in turn amplifies intestinal inflammatory responses, compromises the immune competence of the patient, and thereby directly impedes the trajectory of postoperative convalescence (Hyoung et al., 2018). Moreover, the inflammatory cascade initiated by gastric cancer surgery leads to a marked escalation in the levels of interleukin-6 (IL-6) and tumor necrosis factor- α (TNF- α), concurrent with a diminution in the expression of immunoregulatory cytokines. The concomitant impairment of the intestinal mucosal barrier facilitates the translocation of enteric bacteria, exacerbating enteric inflammation, thereby establishing a deleterious feedback loop (Sánchez-Zauco et al., 2017; Muñoz et al., 2019).

The changes in the gut microbiota caused by surgery have profound effects on the health and postoperative recovery of patients, involving digestion, immune regulation, metabolism, and more (Kau et al., 2011; Pflughoeft and Versalovic, 2012; Shreiner et al., 2015). In terms of digestion and nutrient absorption, the gut microbiota plays a crucial role, helping to break down dietary fiber, synthesize vitamins such as vitamin K and B vitamins, and promote the absorption of minerals. After gastric cancer surgery, changes in the gut microbiota may lead to indigestion and poor nutrient absorption, affecting the patient's nutritional status and recovery. Disruption of the gut microbiota can affect the absorption of vitamin B12 (Degnan et al., 2014; Jun et al., 2016), thereby exacerbating

the patient's nutritional intolerance and anemia symptoms, delaying recovery (Radigan, 2004; Lim et al., 2019). The gut microbiota is also involved in various metabolic pathways, including energy metabolism and lipid metabolism, affecting fat storage and distribution, as well as sugar metabolism, thereby affecting the patient's weight and blood sugar control. Changes in the gut microbiota after surgery may affect these metabolic pathways, increasing the risk of developing metabolic syndrome and type 2 diabetes (Turnbaugh et al., 2006; Turnbaugh et al., 2009; Karlsson et al., 2013). In addition, the gut microbiota is closely related to the host's immune system, and imbalances in the gut microbiota after surgery may lead to decreased immune function, increasing the risk of infection (Rubinstein et al., 2013; Kasai et al., 2016; Yachida et al., 2019).

In the clinical management of gastric cancer, radical surgery is regarded as the most efficacious therapeutic intervention, which includes the extirpation of the tumor, lymph node dissection, and the critical phase of gastrointestinal tract reconstruction. The latter is paramount for the convalescence of patients (Yan et al., 2022; Wu et al., 2023). The reconstruction of the gastrointestinal tract post-gastrectomy is an essential procedure in clinical therapy and has become a central focus within the medical community (Zhou et al., 2020). Currently, the treatment paradigm for gastric cancer is predominantly surgical, complemented by a comprehensive strategy that integrates a multi-disciplinary team (MDT) approach, which is crucial for the holistic management of gastric cancer (Gastric Cancer MDT Expert Consensus, 2017). Gastric cancer predominantly arises in the antral region, and the standard surgical protocol involves a distal gastrectomy accompanied by a D2 lymph node dissection. Post-distal gastrectomy, the reconstruction of the gastrointestinal tract commonly employs techniques such as the Billroth I and II anastomoses, the Roux-en-Y (R-Y) anastomosis, and its variant, the Uncut R-Y Approaches.

Double-tract reconstruction (DTR) is a method of gastrointestinal reconstruction used in gastric cancer surgery, especially after proximal gastrectomy. This technique aims to reduce food reflux and maintain the normal digestive pathway by creating two channels (Chen et al., 2017; Long et al., 2018). In DTR, an esophagojejunal R-Y anastomosis is first performed, followed by a lateral-to-lateral anastomosis between the distal residual stomach and the jejunum 10–15 centimeters away from the esophagojejunal anastomosis, allowing food to enter the distal jejunum through two channels. Its advantages include good anti-reflux effects and less demanding requirements for the residual stomach. Despite the presence of two pathways, this reconstruction method has advantages for the absorption of micronutrients such as vitamin B12 and iron (Kohzadi et al., 2017; Zoroddu et al., 2019). Studies have shown that compared with traditional R-Y anastomosis, DTR can more quickly restore gastrointestinal function (Qiu et al., 2022; Ying et al., 2023). However, there is less research on the impact of postoperative gut microbiota, and this study aims to analyze the effects of different surgical methods on the gut microbiota.

This study delved into the impact of different gastrointestinal reconstruction techniques on the gut microbiota of patients following gastric cancer surgery, which holds significant importance for understanding the complex physiological changes during postoperative recovery. By comparing the DTR with the R-Y

gastrointestinal reconstruction, the study revealed the significant effects of different digestive tract reconstruction methods on the diversity and structure of the gut microbiota. These findings not only provide valuable references for the clinical treatment of gastric cancer surgery but also offer a scientific basis for developing targeted postoperative management strategies, such as nutritional support and infection control.

2 Materials and methods


2.1 Study design

This study was approved by the Biomedical Ethics Committee of Sichuan Mianyang 404 Hospital (Trial No. 028 in 2022). All study patients signed written informed consent. A randomized sampling method was used to select gastric cancer patients who underwent surgical treatment at Sichuan Mianyang 404 Hospital from January 2023 to December 2023 as subjects of the study.

The trial profile is shown in Figure 1. Inclusion criteria: (1) Patients diagnosed with gastric cancer by pathology; (2) Patients with locally advanced gastric cancer scheduled for radical resection; (3) Age ≤ 75 years, both genders included; (4) Performance status score: KPS ≥ 80 ; (5) Willing to participate and have signed the informed consent form; (6) No distant organ metastasis on preoperative examination, and no prior radiotherapy or chemotherapy. Exclusion criteria: (1) Early-stage gastric cancer; (2) Distant metastasis present; (3) Performance status score: KPS < 80 , or overall condition unable to tolerate surgery; (4) History of intestinal surgery, cholecystectomy, or pancreas surgery; (5) History of functional dyspepsia; (6) Severe cardiac, pulmonary, hepatic, or renal insufficiency; (7) Infectious diseases present, or other conditions affecting quality of life; (8) Inability to understand or refusal to sign the informed consent form. Disqualification criteria: (1) Violation of entry criteria; (2) Failure to complete surgery as planned; (3) Missing main indicators, with obviously incomplete data. Withdrawal criteria: (1) Patient's own request to withdraw from the trial; (2) Emergence of other serious medical conditions deemed unrelated to gastrointestinal reconstruction surgery by the investigator; (3) Inability to follow the protocol for follow-up, poor compliance; (4) Emergence of other serious medical conditions preventing completion of follow-up observations.

2.2 Perioperative management

The perioperative management protocol for both cohorts of patients was standardized, encompassing the following measures. Preoperative Preparation Phase: (1) For patients without gastrointestinal motility disorders, they must refrain from consuming any food within 6 h prior to surgery, and within 2 h before the commencement of the surgery, they must completely cease the intake of any liquids. (2) To avoid unnecessary intervention before the surgery, no gastric tube will be placed for the patients. (3) Considering the balance of the intestinal microbiota, within 3 months prior to surgery, patients should not receive any treatments or medications that may affect this balance,



such as probiotics, antibiotics, and proton pump inhibitors. Intraoperative treatment: (1) All surgeries are performed by the same medical team. (2) General anesthesia is administered in all cases. (3) Patients undergo either proximal subtotal gastrectomy or total gastrectomy. (4) The Approaches of gastrointestinal tract reconstruction include R-Y reconstruction or the modified DTR gastrointestinal reconstruction. (5) Prophylactic administration of ceftriaxone 2 grams via intravenous drip is carried out 30 min before surgery. Postoperative treatment: (1) A nasogastric tube is routinely left in place after surgery, typically for a period of 5–6 days. (2) After the removal of the nasogastric tube, patients begin with clear fluids and progress to semi-solid foods on the second day following tube removal. (3) Administer cefuroxime intravenously every 12 h (q12h) at a dosage of 1.5g, or ceftriaxone once daily (qd) at a dosage of 2 grams. (4) Probiotics or other live bacterial preparations are not used before discharge after surgery. (5) All patients receive and follow the dietary guidance provided by our hospital's nutrition department postoperatively.

2.3 Sample collection

Preoperatively (before bowel preparation), blood and fecal samples are collected from patients. A fecal microbiota analysis is conducted on the fresh, medium-to-end segment, internal 2 g fecal samples. The samples are named RQ (preoperative samples of the R-Y group), SQ (preoperative samples of the DTR group), and are immediately frozen at -80°C for preservation. After all patients have completed the relevant preoperative

preparations, they undergo surgical treatment under general anesthesia. Postoperatively, they are all given ceftriaxone (1 g) intravenous infusion every 12 h for infection prevention, which is generally used for 48 h and then discontinued. On the first postoperative day, parenteral nutritional support is initiated for all patients. After the patients resume a liquid diet (porridge or milk) and have a bowel movement of yellow stool, blood and fecal samples are collected again (approximately 1 week postoperatively). The fecal samples are named RH (postoperative samples of the R-Y group), SH (postoperative samples of the DTR group), consistent with the preoperative samples and preserved under the same low-temperature conditions. After all specimens are collected, they are sent together to Beijing Biomarker Technologies Co., LTD. (Beijing, China) for testing and analysis.

2.4 Microbiome analysis

Firstly, the raw reads obtained from sequencing were filtered using the Trimmomatic v0.33 software. Subsequently, the Cutadapt 1.9.1 software was utilized to identify and remove primer sequences, yielding clean reads free of primer sequences. The reads were then processed with the dada2 method in QIIME2 2020.6 (Bolyen et al., 2019) for denoising, merging of paired-end sequences, and the removal of chimeric sequences, resulting in the final valid data (Non-chimeric Reads). Finally, differential biomarkers were sought, and related functional genes were predicted through analyses such as alpha diversity analysis, beta

TABLE 1 Baseline characteristics and outcomes of patients with different surgical approaches.

Parameter	R-Y surgery group (<i>n</i> = 5)	DTR surgery group (<i>n</i> = 5)	<i>P</i>
Age, years mean ± SD	65.2 ± 3.11	68 ± 4.36	0.280
Body mass index kg/m ² , mean ± SD	23.30 ± 4.52	23.41 ± 2.83	0.893
Intraoperative blood loss ml, mean ± SD	18 ± 4.47	26 ± 13.42	0.263
Surgical duration hours, mean ± SD	3.53 ± 0.43	3.4 ± 0.84	0.671
Degree of total protein decrease (TP) g/L, mean ± SD	11.14 ± 9.23	19.74 ± 4.04	0.109
Degree of serum Albumin decrease (ALB) g/L, mean ± SD	6.1 ± 5.16	11.28 ± 3.73	0.110
Degree of Hemoglobin decrease (Hb) g/L, mean ± SD	4.6 ± 5.13	17.8 ± 14.17	0.107
Degree of Leukocyte increase(WBC) g/L, mean ± SD	7.32 ± 5.94	4.46 ± 1.99	0.355
Degree of Neutrophil increase(Neu) g/L, mean ± SD	16.42 ± 17.23	12.58 ± 5.86	0.657

Statistical test performed: two-sample *t*-test for numerical data; *n*, number of participants.

diversity analysis, inter-group difference significance analysis, and functional gene prediction (Kenneth et al., 1975; Ramette, 2007).

2.5 Statistical analysis

The data were processed and analyzed using the R software package. For comparisons between two groups, *t*-test analysis was utilized, while non-parametric rank sum tests were performed using the Kruskal-Wallis (*H*) test and the Wilcoxon test. A *p*-value of less than 0.05 was considered to indicate statistical significance, and a *p*-value of less than 0.01 was regarded as indicating a high level of statistical significance.

3 Results

A total of 20 fecal samples were collected (one serving as a normal control sample), with 5 patients in each of the R-Y surgery group and the DTR surgery group. Patient information and perioperative and postoperative test indicators for the two groups are shown in Table 1 (all *p* > 0.05).

3.1 16S rRNA sequencing

3.1.1 Comparison of α -diversity after different surgical approaches



α -diversity, a key measure in ecological studies, reflects the species abundance and diversity within a single sample. The Chao1 index and Ace index are used to assess the number of species, while the Shannon index and Simpson index evaluate the diversity of species. The PD whole tree index is a phylogenetic diversity index calculated from the representative sequences of operational

taxonomic units (OTUs) in each sample to construct a phylogenetic tree. The sum of the branch lengths of all representative sequences in a sample yields a value that indicates the community's diversity, with higher values suggesting greater diversity.

The *t*-test revealed that the R-Y surgery group had a higher level of species diversity and richness compared to the DTR surgery group. However, no significant differences were found between the indices (all *p*-values > 0.05), as shown in Figure 2. Additionally, we analyzed the α -diversity before and after different surgical approaches. There was no significant difference in the R-Y surgery group (Supplementary Figure 2), while the DTR surgery group showed significant differences in the Chao1 index, Ace index, and PD whole tree (Supplementary Figure 1).

3.1.2 Comparison of β -diversity after different surgical approaches

β -diversity is primarily employed to assess the similarities in the composition of microbial communities across samples and to compare the levels of species diversity among different samples. The β -diversity of the gut microbiota in the R-Y surgery group and the DTR surgery group was analyzed using the NMDS algorithm with weighted UniFrac, as shown in Figure 3A. There is a certain degree of similarity in the microbial composition between the different surgical groups. The Adonis statistical analysis, based on the Bray-Curtis distance algorithm, revealed significant differences in β -diversity between the two groups (*p* = 0.053) (Figure 3B), indicating that different surgical Approaches can affect the structure of the gut microbiota (Figure 3C). In addition, we compared the changes in gut microbiota before and after different surgeries and found that the DTR surgery group could alter the structure of the gut microbiota (Supplementary Figure 3), while there was no significant change in the gut microbiota before and after the R-Y surgery group (Supplementary Figure 4).






FIGURE 4 Phylogenetic analysis of relative abundances at different taxonomic levels for the two groups. (A) Phylum; (B) class; (C) order; (D) family; (E) genus; (F) species (display only the top 10 taxonomic groups by relative abundance at each classification level).

3.1.3 Influence of various surgical approaches on gut microbiota composition and differential microbiota analysis

Through species annotation of sequencing data from samples, the dominant phyla, genera, and species annotated in the SH group are as follows: Phyla, Bacteroidia (41%), Proteobacteria (29%), Firmicutes (15%); Genera, Bacteroides (30%), Fusobacterium (13%), Pseudomonas (10%), Parabacteroides (9%), Enterococcus (5%), Lachnoclostridium (1%); Species, *Bacteroides fragilis* (22%), *Escherichia coli* (18%), *Escherichia Shigella* (18%), *Fusobacterium ulcerans* (13%), *Pseudomonas aeruginosa* (10%), *Parabacteroides distasonis* (6%), *Bacteroides thetaiotaomicron* (4%), *Enterococcus faecium* (4%), *Parabacteroides merdae* (2%). The F/B (Firmicutes/Bacteroidetes) ratio in the SH group is 0.37 (Figures 4, 5A).


For the RH group, the dominant phyla, genera, and species annotated are: Phyla, Bacteroidia (50%), Proteobacteria (13%), Firmicutes (28%); Genera, Enterococcus (28%), Bacteroides (20%), Parabacteroides (6%), Streptococcus (3%), Staphylococcus (2%), Lachnoclostridium (2%), Eggerthella (2%), Alistipes (1%), Corynebacterium (1%), Faecalibacterium (1%), Fusobacterium (1%); Species, *Enterococcus faecium* (27%), *Bacteroides fragilis* (14%), *Escherichia Shigella* (9%), *Escherichia coli* (9%), *Parabacteroides merdae* (4%), *Bilophila wadsworthia* (3%), *Bacteroides thetaiotaomicron* (2%), *Staphylococcus epidermidis* (2%), *[Ruminococcus] gnavus* (2%), *Tyzzera nexilis* (2%), *Streptococcus parasanguinis* (2%), *Eggerthella lenta* (2%), *Parabacteroides distasonis* (1%), *Corynebacterium striatum* (1%), *Faecalibacterium prausnitzii* (1%), *Clostridioides difficile* (1%), *Bacteroides uniformis* (1%), *Fusobacterium ulcerans* (1%), *[Clostridium] symbiosum* (0.6%), *Streptococcus constellatus* (0.9%), *Parabacteroides johnsonii* (0.9%), *Phocaeicola vulgatus* (0.9%),

Alistipes onderdonkii (0.8%), *Rahnella aquatilis* (0.8%), *Abiotrophia defectiva* (0.6%). The F/B (Firmicutes/Bacteroidetes) ratio in the RH group is 0.56 (Figures 4, 5B).

LEfse (Linear Discriminant Analysis Effect Size) analysis results indicate that compared to the RH group, the SH group has significant differences in 1 bacterial family, 2 genera, and 7 species; in contrast, compared to the SH group, the RH group has significant differences in 1 phylum, 2 classes, 2 orders, 1 family, 1 genus, and 1 species. In the SH group, the significantly altered bacterial family is Porphyromonadaceae; the significantly altered genera are Porphyromonas and Citrobacter; the significantly altered species are *Pseudomonas aeruginosa*, *Parabacteroides distasonis*, *Prevotella sp Marseille P4119*, *Enterococcus gallinarum*, unclassified Fusobacterium, *Porphyromonas somerae*, and *Citrobacter freundii*. In the RH group, the significantly altered phylum is Firmicutes; the significantly altered classes are Bacilli and Actinobacteria; the significantly altered orders are Clostridia vadinBB60 group and Lactobacillales; the significantly altered family, genus, and species are unclassified Clostridia vadinBB60 group (Figure 6).

3.2 Metabolomic pathway prediction analysis of different surgical approaches

To further assess the functionality and role of the host gut microbiota, this study employed the PICRUSt2 software to predict the functional pathways of the 16S rRNA genes of the gut microbiota following two different surgical approaches. The pathway analysis by PICRUSt2 indicated no significant differences between the RH and SH groups ($P > 0.05$). However, upon



comparing RH1 and SH1, we found that a total of 39 metabolic pathways exhibited significant changes. Compared between the two groups, 15 pathways were upregulated in the RH1 group ($P < 0.05$), while the remaining 24 pathways were downregulated in the SH1 group ($P < 0.05$). These functional pathways are primarily concentrated in metabolic routes involving amino acid metabolism, glycometabolism, nucleotide metabolism, and carbohydrate metabolism, as shown in Figure 7. The gut microbiota affected by the two distinct surgical approaches participated in multiple metabolic pathways, with the SH1 group activating more metabolic pathways compared to the RH1 group.

4 Discussion

Gastric cancer is one of the most common malignant tumors in the digestive system, ranking fifth in incidence and fourth in mortality among the most common malignant tumors worldwide (Sung et al., 2021). The normal gastric mucosa undergoes a progressive sequence of changes from non-atrophic gastritis, atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia, and ultimately to gastric cancer. To date, surgery is still considered the only definitive treatment method. However, surgery can induce stress responses in the patient's body, including inflammation,




FIGURE 6 Analysis of the differences in gut microbiota after different surgical approaches. (A) LEfSe analysis providing phylum-to-species phylogenetic distribution; (B) LDA scores identifying differential entities between the two groups (LDA score ≥ 4 , 0).




FIGURE 7 Functional prediction analysis of metabolic pathways of differential biological functions. (A) KEGG pathway abundance at the species level; (B) differences in metabolism between groups.

ischemia-reperfusion injury (IRI), activation of the sympathetic nervous system, and increased release of cytokines (Chen et al., 2019). In recent years, with the development and widespread clinical application of next-generation sequencing technology, many researchers have found that the gut microbiota plays an important role in the occurrence and development of various diseases, especially in cancer (Abdi et al., 2021; Fernandes et al., 2022; Wong et al., 2023).

In this study, we compared the α -diversity of the gut microbiota postoperatively between the R-Y surgery group and the DTR surgery group, and no significant differences were found, indicating that different surgical approaches do not affect the total number of species, that is, the absolute number of species in the gut microbiota. Regarding the β -diversity of the gut microbiota, we found significant differences between the two groups, indicating that different surgical methods can impact the structure of the gut microbiota. Postoperatively, the species significantly enriched in the DTR surgery group postoperatively include *Pseudomonas aeruginosa*, *Parabacteroides distasonis*, *Enterococcus gallinarum*, *Porphyromonas somerae*, and *Citrobacter freundii*, among which *Pseudomonas aeruginosa*, *Enterococcus gallinarum*, *Porphyromonas somerae*, and *Citrobacter freundii* are conditional pathogens that have significant impacts on the occurrence and progression of cancer, as well as postoperative infections (Caselli et al., 2019; Li et al., 2018; Dziri et al., 2022; Nagre et al., 2022). *Pseudomonas aeruginosa* possesses a high level of antibiotic resistance and can release low molecular weight molecules as chemical signals to regulate the host's immune response (Miller and Bassler, 2001; Romero et al., 2011), thereby posing a serious threat to the recovery of postoperative patients (Aliaga et al., 2002; Maeda et al., 2012). *Enterococcus gallinarum* is commonly found in pulmonary and biliary infections, leading to symptoms such as fever and respiratory distress in patients post-surgery (Liu et al., 2024; He et al., 2024). In studies related to lung cancer, *Porphyromonas somerae* has been found to be significantly enriched (Yuan et al., 2023), which may be related to postoperative infections that lead to the formation of lung cancer. *Citrobacter freundii* can cause a variety of infections, with urinary tract infections being one of them, leading to symptoms such as frequent urination, urgency, pain during urination, and even hematuria in patients (Huang et al., 2023). *Parabacteroides distasonis* is a beneficial bacterium that can play a protective role in certain diseases (Le et al., 2015; Spinler et al., 2017; Chai et al., 2017). It is widely distributed in the gastrointestinal tracts of humans and animals, and is a Gram-negative, non-spore-forming, rod-shaped strict anaerobe (Rea et al., 2010). It can convert primary bile acids into secondary bile acids and alleviate metabolic disorders by regulating bile acid metabolism (Kang et al., 2019), and moreover, can improve some postoperative symptoms, such as inflammatory bowel disease, by producing or stimulating the host to produce various active metabolites (Zhao et al., 2023).

In the R-Y surgery group, we found an enrichment of Clostridia and Lactobacillales. Clostridia belong to the phylum Firmicutes, are facultative anaerobic bacteria, and mainly consist of beneficial and harmful clostridia, which are very important for the physiological and pathological development of the body. Some are mainly used for the prevention, diagnosis, or treatment

of diseases (Miquel et al., 2013; Xie et al., 2016), and some have been proven to be closely related to the occurrence and development of certain human diseases (Spitzer and Ratzan, 1991; Shinha and Hadi, 2015). The Lactobacillales is an important group of probiotics that can synthesize substances such as bacteriocins, organic acids, and polysaccharides, which exhibit activities with antimicrobial, antioxidant, and antitumor properties (Li et al., 2014; Li et al., 2015; Wang et al., 2018). In addition, our analysis also revealed that the R-Y surgery group has a higher F/B (Firmicutes/Bacteroidetes) ratio compared to the DTR surgery group. Firmicutes and Bacteroidetes are the dominant bacterial groups in mammals, accounting for more than 90% of the gut microbiota (Human Microbiome Project Consortium, 2012). Their ratio is commonly used to assess the degree of gut microbial dysbiosis (Zhang et al., 2015), with a higher ratio being more conducive to nutrient absorption and energy storage (Zhang et al., 2021).

In the analysis of the gut microbiota of patients undergoing two different surgical procedures, patients in the DTR group were found to have a higher enrichment of bacteria associated with postoperative infections, which may be related to symptoms such as pulmonary infection, reduced gastrointestinal motility, and gastroesophageal reflux disease. This is consistent with studies conducted in the follow-up of patients after gastric cancer surgery (Li et al., 2024; Peng et al., 2024; Sun et al., 2024). Compared to the DTR group, although the R-Y group had more beneficial bacteria and a smaller amount of pathogenic bacteria detected, it does not necessarily prove that the R-Y surgical approach is superior to the DTR surgical approach. Comparative analyses related to DTR and R-Y surgical methods have shown that the DTR surgical approach is superior to the R-Y surgical approach in terms of short-term nutritional status after surgery and long-term vitamin B12 levels (Qiu et al., 2022). Therefore, when choosing a specific surgical method for gastric cancer patients, a comprehensive comparison and analysis should be made.

This study also has certain limitations. Firstly, there is not a large sample size, which does not adequately reflect the changes in the gut microbiota after surgery. Additionally, no analysis or detection of metabolites was conducted, nor was further verification in animal models, so it is not possible to specifically analyze which metabolites play a role in postoperative infection and the pathways they affect.

Data availability statement

The original contributions presented in the study are publicly available. This data can be found here: <https://www.ncbi.nlm.nih.gov/sra>, accession number SRP558847.

Ethics statement

This study has been approved by the Biomedical Ethics Committee of Mianyang 404 Hospital (Approval Number: Trial

No. 028 in 2022), and all participants have signed informed consent forms agreeing to participate in this study.

Author contributions

YY: Writing – original draft, Writing – review and editing. G-MZ: Writing – original draft. JC: Writing – original draft. RM: Writing – original draft. DZ: Writing – original draft. H-WJ: Writing – review and editing. H-YZ: Writing – review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was financially supported by the Mianyang City Science and Technology Bureau's 2019 Applied Technology Research and Development Project (2019YFZJ020) and the Special Fund Project of the Mianyang Municipal Health Commission (202205).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

- Abdi, E., Latifi-Navid, S., Sarvestani, F. A., and Esmailnejad, M. (2021). Emerging therapeutic targets for gastric cancer from a Host-*Helicobacter pylori* interaction perspective. *Expert Opin. Ther. Targets* 25, 685–699. doi: 10.1080/14728222.2021.1971195
- Aliaga, L., Mediavilla, J. D., and Cobo, F. (2002). A clinical index predicting mortality with *Pseudomonas aeruginosa* bacteraemia. *J. Med. Microbiol.* 51, 615–701. doi: 10.1099/0022-1317-51-7-615
- Bolyen, E., Rideout, J., Dillon, M., Bokulich, N., Abnet, C., Al-Ghalith, G., et al. (2019). Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol.* 37, 852–857. doi: 10.1038/s41587-019-0209-9
- Caselli, E., Soffritti, I., D'Accolti, M., Piva, I., Greco, P., Bonaccorsi, G., et al. (2019). *Atopobium vaginae* and *Porphyromonas somerae* induce proinflammatory cytokines expression in endometrial cells: A possible implication for endometrial cancer? *Canc. Manag. Res.* 11, 8571–8575. doi: 10.2147/CMAR.S217362
- Chai, C., Lee, K. S., Imm, G. S., Kim, Y., and Oh, S. (2017). Inactivation of *Clostridium difficile* spore outgrowth by synergistic effects of nisin and lysozyme. *Can. J. Microbiol.* 63:638. doi: 10.1139/cjm-2016-0550
- Chen, Y., Zhang, S. P., and Guo, S. P. (2017). Survival analysis after curative surgery in 269 patients with adenocarcinoma of the esophagogastric junction. *Tumor Res. Clin. Oncol.* 29, 819–823.
- Chen, Z., Zhang, P., Xu, Y., Yan, J., Liu, Z., Lau, W., et al. (2019). Surgical stress and cancer progression: The twisted tango. *Mol. Cancer* 18:132. doi: 10.1186/s12943-019-1058-3
- Degnan, P. H., Taga, M. E., and Goodman, A. (2014). Vitamin B 12 as a modulator of gut microbial ecology. *Cell Metab.* 20, 769–778. doi: 10.1016/j.cmet.2014.10.002
- Dziri, R., Kuşkuç, M. A., Arfaoui, A., Fethi, M., Ifaoui, S., Bellaaj, R., et al. (2022). Whole genome sequencing of a *Citrobacter freundii* strain isolated from the hospital environment: An extremely multiresistant NDM-1 and VIM-48 coproducing isolate. *Microbial Drug Resistance* 28, 18–22. doi: 10.1089/mdr.2020.0417
- Fernandes, M., Aggarwal, P., Costa, R., Cole, A., and Trinchieri, G. (2022). Targeting the gut microbiota for cancer therapy. *Nat. Rev. Cancer* 22, 703–722. doi: 10.1038/s41568-022-00513-x
- Gastric Cancer MDT Expert Consensus (2017). Chinese research hospital association gastrointestinal oncology special committee & Chinese medical doctor association surgeons branch multidisciplinary comprehensive treatment special committee. *Chin. J. Practical Surg.* 37, 37–38. doi: 10.19538/j.cjps.issn1005-2208.2017.01.12
- GBD 2017 Stomach Cancer Collaborators (2020). The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: A systematic analysis for the global burden of disease study 2017. *Lancet Gastroenterol. Hepatol.* 5, 42–54. doi: 10.1016/S2468-1253(19)30328-0
- He, C. L., Chen, L., Zhao, L. S., Lin, H. X., Liu, M. Z., Chen, E., et al. (2024). Biliary tract infections caused by *Enterococcus gallinarum* and *Escherichia coli*: A rare case report. *Future Microbiol.* doi: 10.1080/17460913.2024.2417597 Online ahead print.
- Huang, R., Yuan, Q., Gao, J., Liu, Y., Jin, X., Tang, L., et al. (2023). Application of metagenomic next-generation sequencing in the diagnosis of urinary tract infection in patients undergoing cutaneous ureterostomy. *Front. Cell Infect. Microbiol.* 13:991011. doi: 10.3389/fcimb.2023.991011
- Human Microbiome Project Consortium (2012). Structure, function and diversity of the healthy human microbiome. *Nature* 486, 207–214. doi: 10.1038/nature11234
- Hyoun, C. O., Myung, G. C., Jae, M. P., Song, K., and Yoo, H. (2018). Acid secretion and its relationship to esophageal reflux symptom in patients with subtotal gastrectomy. *Digestive Dis. Sci.* 63, 703–712. doi: 10.1007/s10620-018-4923-9
- Jun, J. H., Yoo, J. E., Lee, J. A., Kim, Y., Sunwoo, S., Kim, B., et al. (2016). Anemia after gastrectomy in long-term survivors of gastric cancer: A retrospective cohort study. *Int. J. Surg.* 28, 162–168. doi: 10.1016/j.ijsu.2016.02.084
- Kanda, M., Ito, S., Mochizuki, Y., Teramoto, H., Ishigure, K., Murai, T., et al. (2019). Multi-institutional analysis of the prognostic significance of postoperative complications after curative resection for gastric cancer. *Cancer Med.* 8, 5194–5201. doi: 10.1002/cam4.2439

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2024.1494049/full#supplementary-material>

SUPPLEMENTARY FIGURE 1

Comparison of preoperative and postoperative gut microbiota α -diversity in the DTR surgery group. (A) ACE index; (B) Chao1 index; (C) PD whole tree index; (D) Shannon index; (E) Simpson index.

SUPPLEMENTARY FIGURE 2

Comparison of preoperative and postoperative gut microbiota α -diversity in the R-Y surgery group. (A) ACE index; (B) Chao1 index; (C) PD whole tree index; (D) Shannon index; (E) Simpson index.

SUPPLEMENTARY FIGURE 3

Analysis of gut microbiota β -diversity pre- and post-surgery in the DTR surgery group. (A) PCA analysis; (B) PerMANOVA analysis; (C) UPGMA clustering tree using weighted UniFrac distances.

SUPPLEMENTARY FIGURE 4

Analysis of gut microbiota β -diversity pre- and post-surgery in the R-Y surgery group. (A) PCA analysis; (B) PerMANOVA analysis; (C) UPGMA Clustering tree using weighted UniFrac distances.

- Kang, J. D., Myers, C. J., Harris, S. C., Kakiyama, G., Lee, I., Yun, B., et al. (2019). Bile acid 7 α -Dehydroxylating gut bacteria secrete antibiotics that inhibit clostridium difficile: Role of secondary bile acids. *Cell Chem. Biol.* 26:27. doi: 10.1016/j.chembiol.2018.10.003
- Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C., Fagerberg, B., et al. (2013). Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* 498, 99–103. doi: 10.1038/nature12198
- Kasai, C., Sugimoto, K., Moritani, I., Tanaka, J., Oya, Y., Inoue, H., et al. (2016). Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. *Oncol. Rep.* 35, 325–333. doi: 10.3892/or.2015.4398
- Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L., and Gordon, J. I. (2011). Human nutrition, the gut microbiome and the immune system. *Nature* 474, 327–336. doi: 10.1038/nature10213
- Kenneth, L. H., Gerald, V. B., and Daniel, S. (1975). Explicit calculation of the rarefaction diversity measurement and the determination of sufficient sample size. *Ecology* 56, 1459–1461. doi: 10.2307/1934716
- Kohzadi, S., Sheikhesmaili, F., Rahehagh, R., Parhizkar, B., Ghaderi, E., Loqmani, H., et al. (2017). Evaluation of trace element concentration in cancerous and non-cancerous tissues of human stomach. *Chemosphere* 184, 747–752. doi: 10.1016/j.chemosphere.2017.06.071
- Kubota, T., Hiki, N., Sano, T., Nomura, S., Nunobe, S., Kumagai, K., et al. (2014). Prognostic significance of complications after curative surgery for gastric cancer. *Ann. Surg. Oncol.* 21, 891–898. doi: 10.1245/s10434-013-3384-9
- Laukens, D., Brinkman, B. M., Raes, J., Martine, D. V., and Vandenabeele, P. (2016). Heterogeneity of the gut microbiome in mice: Guidelines for optimizing experimental design. *FEMS Microbiol. Rev.* 40, 117–132. doi: 10.1093/femsre/fuv036
- Le, L. C., Fernandez, B., Hammami, R., Ouellette, M., and Fliss, I. (2015). On *Lactococcus lactis* UL719 competitiveness and nisin (Nisaplin) capacity to inhibit clostridium difficile in a model of human colon. *Front. Microbiol.* 6:1020. doi: 10.3389/fmicb.2015.01020
- Li, W., Ji, J., Tang, W., Rui, X., Chen, X., Jiang, M., et al. (2014). Characterization of an antiproliferative exopolysaccharide (LHEPS-2) from *Lactobacillus helveticus* MB2-1. *Carbohydrate Polym.* 105, 334–340. doi: 10.1016/j.carbpol.2014.01.093
- Li, W., Xia, X., Tang, W., Ji, J., Rui, X., Chen, X., et al. (2015). Structural characterization and anticancer activity of cell-bound exopolysaccharide from *Lactobacillus helveticus* MB2-1. *J. Agric. Food Chem.* 63, 3454–3463. doi: 10.1021/acs.jafc.5b01086
- Li, X., Fan, S., Lin, X., Liu, L., Zheng, J., Zhou, X., et al. (2018). The first case report of *Enterococcus gallinarum* meningitis in neonate. *Medicine* 97:e9875. doi: 10.1097/md.00000000000009875
- Li, Y. Y., Wu, J., Han, M., Li, W. B., and Bi, Z. B. (2024). Modified double-tract reconstruction in gastrointestinal reconstruction after proximal gastrectomy. *J. Coll. Physicians Surg. Pak.* 34, 1374–1377. doi: 10.29271/jcpsp.2024.11.1374
- Lim, J., Yoo, M. W., Kang, S. Y., and Park, H. (2019). Long-Term changes in the metabolic and nutritional parameters after gastrectomy in early gastric cancer patients with overweight. *Asian J. Surg.* 42, 386–393. doi: 10.1016/j.asjsur.2018.06.011
- Liu, M., Liu, J. X., Wu, J. J., Liu, S., Sun, L., Li, F., et al. (2024). A case report of empyema caused by *Enterococcus gallinarum*. *BMC Infect Dis.* 24:769. doi: 10.1186/s12879-024-09531-6
- Long, A. J., Burton, P. R., De, V. M., Ooi, G., Laurie, C., Nottle, P., et al. (2012). Radical gastric cancer surgery results in widespread upregulation of pro-tumorigenic intraperitoneal cytokines. *ANZ J. Surg.* 88, 370–376. doi: 10.1111/ans.14267
- Maeda, T., García-Contreras, R., Pu, M., Sheng, L., García, L., Tomás, M., et al. (2012). Quorum quenching quandary: Resistance to antivirulence compounds. *ISME J.* 6, 493–501. doi: 10.1038/ismej.2011.122
- Miller, M. B., and Bassler, B. L. (2001). Quorum sensing in bacteria. *Annu. Rev. Microbiol.* 55, 165–199. doi: 10.1146/annurev.micro.55.1.165
- Miquel, S., Martín, R., Rossi, O., Bermúdez-Humarán, L., Chatel, J., Sokol, H., et al. (2013). Faecalibacterium prausnitzii and human intestinal health. *Curr. Opin. Microbiol.* 16, 255–261. doi: 10.1016/j.mib.2013.06.003
- Moossavi, S., and Azad, M. B. (2019). Quantifying and interpreting the association between early-life gut microbiota composition and child-hood obesity. *mBio* 10:e02787-18. doi: 10.1128/mBio.02787-18
- Muñoz, L., Borrero, M. J., Úbeda, M., Conde, E., Del Campo, R., Rodríguez-Serrano, M., et al. (2019). Intestinal immune dys-regulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis. *Hepatology* 70, 925–938. doi: 10.1002/hep.30349
- Nagre, N., Nicholson, G., Cong, X., Lockett, J., Pearson, A., Chan, V., et al. (2022). Activation of cannabinoid-2 receptor protects against *pseudomonas aeruginosa* induced acute lung injury and inflammation. *Respir. Res.* 23:326. doi: 10.1186/s12931-022-02253-w
- Peng, R., Shi, Y., Zhang, H., Xie, Q. Y., Yue, C., Huang, L., et al. (2024). Tunnel anastomosis: A modified flap technique in esophagogastrectomy as a novel antireflux technique after proximal gastrectomy. *J. Gastrointest. Surg.* doi: 10.1016/j.gassur.2024.10.026 Online ahead of print.
- Pflughoeft, K. J., and Versalovic, J. (2012). Human microbiome in health and disease. *Annu. Rev. Pathol.* 7, 99–122. doi: 10.1146/annurev-pathol-011811-132421
- Pizzato, M., Li, M., Vignat, J., Laversanne, M., Singh, D., la Vecchia, C., et al. (2022). The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. *Lancet Diabetes Endocrinol.* 10, 264–272. doi: 10.1016/S2213-8587(22)00035-3
- Qiu, G. L., Wei, C., Zhu, M. K., Han, S. N., Li, X. W., Wang, H. J., et al. (2022). Efficacy of laparoscopic proximal gastrectomy with double-tract reconstruction versus laparoscopic total gastrectomy with Roux-en-Y reconstruction for early upper gastric cancer. *Zhonghua Wei Chang Wai Ke Za Zhi* 25, 412–420. doi: 10.3760/cma.j.cn441530-20211118-00466
- Radigan, A. E. (2004). Post-Gastrectomy: Managing the nutrition fallout. *Pract. Gastroenterol.* 28, 63–79.
- Ramette, A. (2007). Multivariate analyses in microbial ecology. *FEMS Microbiol. Ecol.* 62, 142–160. doi: 10.1111/j.1574-6941.2007.00375.x
- Rea, M. C., Sit, C. S., Clayton, E., O'Connor, P., Whittal, R., Zheng, J., et al. (2010). Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against *Clostridium difficile*. *Proc. Natl. Acad. Sci. USA* 107, 9352–9357. doi: 10.1073/pnas.0913554107
- Romero, M., Muro-Pastor, A. M., and Otero, A. (2011). Quorum sensing N-acylhomoserine lactone signals affect nitrogen fixation in the cyanobacterium *Anabaena* sp. PCC7120. *FEMS Microbiol. Lett.* 315, 101–108. doi: 10.1111/j.1574-6968.2010.02175.x
- Rubinstein, M. R., Wang, X., Liu, W., Hao, Y., Cai, G., Han, Y., et al. (2013). *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-Cadherin/ β -Catenin signaling via its FadA adhesin. *Cell Host Microbe* 14, 195–206. doi: 10.1016/j.chom.2013.07.012
- Sánchez-Zaucar, N., Torres, J., Gómez, A., Camorlinga-Ponce, M., Muñoz-Pérez, L., Herrera-Goepfert, R., et al. (2017). Circulating blood levels of IL-6, IFN- γ , and IL-10 as potential diagnostic biomarkers in gastric cancer: A controlled study. *BMC Cancer* 17:384. doi: 10.1186/s12885-017-3310-9
- Shinha, T., and Hadi, C. (2015). Clostridium paraputrificum bacteremia associated with colonic necrosis in a patient with AIDS. *Case Rep. Infect. Dis.* 2015:312919. doi: 10.1155/2015/312919
- Shreiner, A. B., Kao, J. Y., and Young, V. B. (2015). The gut microbiome in health and in disease. *Curr. Opin. Gastroenterol.* 31, 69–75. doi: 10.1097/MOG.0000000000000139
- Spinler, J. K., Auchtung, J., Brown, A., Boonma, P., Oezguen, N., Ross, C., et al. (2017). Next-generation probiotics targeting clostridium difficile through precursor-directed antimicrobial biosynthesis. *Infect. Immun.* 85, e303–e317. doi: 10.1128/iai.00303-17
- Spitzer, R. D., and Ratzan, K. R. (1991). Chronic osteomyelitis due to Clostridium clostridiiforme. *South Med. J.* 84, 671–672.
- Sun, Y., Chen, C., Hou, L., and Zhao, E. H. (2024). Short-term outcomes and quality of life of esophagogastrectomy versus the double-tract reconstruction after laparoscopic proximal gastrectomy. *BMC Cancer* 24:1324. doi: 10.1186/s12885-024-13095-8
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *Cancer J. Clin.* 71, 209–249. doi: 10.3322/caac.21660
- Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B., Duncan, A., Ley, R., et al. (2009). A core gut microbiome in obese and lean twins. *Nature* 457, 480–484. doi: 10.1038/nature07540
- Turnbaugh, P. J., Ley, R., Mahowald, M., Magrini, V., Mardis, E., Gordon, J., et al. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 444, 1027–1031. doi: 10.1038/nature05414
- Wang, Y., Qin, Y., Xie, Q., Zhang, Y., Hu, J., Li, P., et al. (2018). Purification and characterization of plantaricin LPL-1, a novel class IIa bacteriocin produced by *Lactobacillus plantarum* LPL-1 isolated from fermented fish. *Front. Microbiol.* 9:2276. doi: 10.3389/fmicb.2018.02276
- Wong, S. H., Yu, J., Wong, S. H., and Lai, D. (2023). Gut microbiota in colorectal cancer development and therapy. *Nat. Rev. Clin. Oncol.* 20, 429–452. doi: 10.1038/s41571-023-00766-x
- Wu, Z., Zhou, Z. G., Li, L. Y., Gao, W., and Yu, T. (2023). Optimal choice of stapler and digestive tract reconstruction method after distal gastrectomy for gastric cancer: A prospective case-control study. *World J. Gastrointestinal Surg.* 15, 1354–1362. doi: 10.4240/wjgs.v15.i7.1354
- Xie, G., Wang, X., Liu, P., Wei, R., Chen, W., Rajani, C., et al. (2016). Distinctly altered gut microbiota in the progression of liver disease. *Oncotarget* 7, 19355–19366. doi: 10.18632/oncotarget.8466

- Yachida, S., Mizutani, S., Shiroma, H., Chen, J., Song, C., Xu, J., et al. (2019). Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. *Nat. Med.* 25, 968–976. doi: 10.1038/s41591-019-0458-7
- Yan, Y., Wang, D., Liu, Y., Lu, L., Wang, X., Zhao, Z., et al. (2022). Optimal reconstruction after laparoscopic distal gastrectomy: A single-center retrospective study. *Cancer Control* 29, doi: 10.1177/107327482211087059
- Ying, K., Bai, W., Yan, G., Xu, Z., Du, S., Dang, S., et al. (2023). The comparison of long-term oncological outcomes and complications after proximal gastrectomy with double tract reconstruction versus total gastrectomy for proximal gastric cancer. *World J. Surg. Oncol.* 21:101. doi: 10.1186/s12957-023-02985-z
- Yuan, Q., Wang, X., Li, Z., Guo, W., Cheng, H., and Cao, Q. (2023). A preliminary study on microbiota characteristics of bronchoalveolar lavage fluid in patients with pulmonary nodules based on metagenomic next-generation sequencing. *Biomedicines* 11:631. doi: 10.3390/biomedicines11020631
- Zhang, X., Zhang, D., Jia, H., Feng, Q., Wang, D., Liang, D., et al. (2015). The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat. Med.* 2, 895–905. doi: 10.1038/nm.3914
- Zhang, Y. Y., Liu, S. J., Feng, Y. Z., and Zhang, X. W. (2021). Bacterial flora composition of normal and diarrhea yak calves based on 16S rRNA sequencing. *China Anim. Husbandry Veterinary Med.* 48, 3293–3302.
- Zhao, Q., Dai, M. Y., Huang, H. Y., Duan, J. Y., and Zhang, T. (2023). Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice. *Nat. Commun.* 14:1829. doi: 10.1038/s41467-023-37459-z
- Zhou, W., Dong, C. Z., Zang, Y. F., Xue, Y., Zhou, X., Wang, Y., et al. (2020). Initial experience of single-incision plus one port left-side approach totally laparoscopic distal gastrectomy with uncut R-Y reconstruction. *World J. Gastroenterol.* 26, 4669–4679.
- Zoroddu, M. A., Aaseth, J., Crisponi, G., Medici, S., Peana, M., Nurchi, V., et al. (2019). The essential metals for humans: A brief overview. *J. Inorg. Biochem.* 195, 120–129. doi: 10.1016/j.jinorgbio.2019.03.013